AXL has been identified as a predictor of poor prognosis for several types of malignancies, including breast cancer, pancreatic cancer, lung adenocarcinoma, osteosarcoma, oral squamous cell carcinoma, and acute myeloid leukemia [18, 19, 21, 22, 46–48]. This evidence concerns the gene AXL and pancreatic neoplasm.